The companies collaborated to evaluate PRT2527 (CDK9 inhibitor) + zanubrutinib (BTK inhibitor) in patients with hematologic malignancies. PRT2527 is being studied as monotx. in a P-I dose-escalation study for advanced solid tumors & r/r hematologic malignancies
BeiGene will be responsible to provide zanubrutinib to Prelude while Prelude will hold all global operational, development, and commercialization rights and responsibilities for PRT2527
PRT2527 was highly effective in preclinical models at well-tolerated doses & decreased MCL1 and MYC protein levels in preclinical studies. In comparison to less selective CDK9 inhibitors, the treatment showed high potency & kinase selectivity which also improved efficacy and safety
Ref: Globenewswire | Image: BeiGene
Related News:- BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia
